About Reticulon-4 receptor
Reticulon-4 receptor (RTN4R) is a protein
from Homo sapiens identified by UniProt accession
Q9BZR6, 473 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Reticulon-4 receptor |
| UniProt accession | Q9BZR6 |
| Gene | RTN4R |
| Organism | Homo sapiens |
| Length | 473 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (110)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.68
- blood protein measurement · score 0.35
- neurodegenerative disease · score 0.32
- head and neck malignant neoplasia · score 0.11
- neoplasm · score 0.10
- experimental autoimmune encephalomyelitis · score 0.10
- glioblastoma multiforme · score 0.08
- Spinal cord injury · score 0.07
- Autosomal dominant striatal neurodegeneration · score 0.05
- lymphatic system disease · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BZR6-F1 | alphafold | PREDICTED | 75.13 | — |
Amino-acid sequence (473 residues)
MKRASAGGSR LLAWVLWLQA WQVAAPCPGA CVCYNEPKVT TSCPQQGLQA VPVGIPAASQ RIFLHGNRIS HVPAASFRAC RNLTILWLHS NVLARIDAAA FTGLALLEQL DLSDNAQLRS VDPATFHGLG RLHTLHLDRC GLQELGPGLF RGLAALQYLY LQDNALQALP DDTFRDLGNL THLFLHGNRI SSVPERAFRG LHSLDRLLLH QNRVAHVHPH AFRDLGRLMT LYLFANNLSA LPTEALAPLR ALQYLRLNDN PWVCDCRARP LWAWLQKFRG SSSEVPCSLP QRLAGRDLKR LAANDLQGCA VATGPYHPIW TGRATDEEPL GLPKCCQPDA ADKASVLEPG RPASAGNALK GRVPPGDSPP GNGSGPRHIN DSPFGTLPGS AEPPLTAVRP EGSEPPGFPT SGPRRRPGCS RKNRTRSHCR LGQAGSGGGG TGDSEGSGAL PSLTCSLTPL GLALVLWTVL GPC
Explore Reticulon-4 receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets